Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 273 No 7327 p785
27 November 2004

This article
Reprint   Photocopy

PDF 90K, Acrobat Reader

Letters

· Registration exam (2)
· Pharmacist prescribing
· Agenda for change
· New contract (3)
· Retention fees (2)
· Statins
· Levothyroxine
· The Journal


Letters to the Editor

Statins

Misleading advertising?

From Mr I. R. MacKillop, MRPharmS

May I draw your attention to the advertisement for Johnson & Johnson MSD’s over-the-counter statin, Zocor Heart-Pro, which appeared in the Independent on Sunday on 7 November [and appears in The Journal this week (pA3)]. If we are to assume that the man in the picture is supposed to be the one saying the words in quotation marks, then something, somewhere, is wrong. First, he has fewer chins than me, so he is not obese, and secondly, from the condition of his skin, if he was ever in the habit of smoking he did the smart thing years ago.

This means that the only possible reason for any pharmacist conversant with the protocols laid down by Johnson & Johnson to supply him with Zocor Heart-Pro is a family history of hyperlipidaemia, which is mentioned nowhere in the quotation marks. There is a get-out clause further down in which it makes clear that 45- to 55-year-old men have to have one of these three additional factors for the risk to be as high as one in seven, but how many punters read every word of an advertisement? Most, if not all, read the headline and base their decision on that. And what is your average 45-year-old male going to decide? That they have a one in seven chance of getting a heart attack and they had better get some Zocor Heart-Pro. Whereupon, if they look like the guy in the photograph and have no hyperlipidaemia in the family they will be told by us pharmacists, politely but firmly, to be on their way. At which point, we pharmacists will be called unfeeling, unprofessional monsters (or worse) for refusing to sell them the medicine they need to save their lives.

Ian MacKillop
Ilminster, Somerset

 

CAROLINE O’DWYER, marketing manager, Johnson & Johnson.MSD, replies:

The purpose of the man featured within the Zocor Heart-Pro advertising is to represent someone who may benefit from being recommended an over-the-counter statin. Such individuals are appropriate for a recommendation if they have a 10–15 per cent (or one in 10 to one in seven) risk of a heart attack in the next 10 years, and can be identified by assessing their age and the presence of specific risk factors for heart disease. These criteria are clearly stated within the advertising text. The advertising also directs individuals to discuss their risk status and eligibility for Zocor Heart-Pro with their pharmacist as a key next step.

The headline of the advertisement makes it clear that this individual is 45 years old. Age is the major driver for cardiovascular risk: men from the age of 45 years and women from the age of 55 years have steeply increasing risk in the remaining decades of life. This “baseline” risk is 10–15 per cent for the male population over 55 years. However, for younger men, ie, those 45 years and over, a further risk factor is required before the risk would fall into this category. Although it is obvious from the visual that this individual does not qualify as a result of being overweight, it is entirely possible that he may qualify as a result of having a family history of early heart disease, or alternatively that he is a smoker (current or has given up within the past five years).

If an individual aged 45 presents without other risk factors for CHD, then it is appropriate that a pharmacist alert the individual to the fact that their risk level is not high enough to justify treatment with Zocor Heart-Pro, and encourage the individual to continue with their healthy heart lifestyle. Rather than find the pharmacist “unfeeling” or “unprofessional monsters”, it is more likely that the customer would be relieved to hear this advice.

In summary we believe our national press advertising campaign is a responsible and measured attempt to increase awareness of CHD risk among the population most likely to benefit from reducing that risk. This population is clearly defined within the text of the advertisement, and readers are directed to check with a pharmacist to ensure that the product is right for them. It is also important to note that all of our advertising material has been approved by the Medicines and Healthcare products Regulatory Agency as being in line with the summary of product characteristics for Zocor Heart-Pro. Furthermore the advertising material has also been fully reviewed by the Proprietary Association of Great Britain for compliance with the self-medication industry’s codes of practice for over-the-counter medicines.

Send your letter to The Editor

Previous Topic (Retention fees)
Next Topic (Levothyroxine)

Back to Top


©The Pharmaceutical Journal